**Citation analysis does not provide a reliable assessment of core outcome set uptake**

**Authors:** Karen L Barnesa, Jamie J Kirkhama, Mike Clarkeb, Paula R Williamsona

**Affiliations**

aMRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom

bCentre for Public Health, Institute of Clinical Sciences, Block B, Queen’s University Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, United Kingdom

**Author email addresses**

Karen.Barnes@liverpool.ac.uk

jjk@liverpool.ac.uk

m.clarke@qub.ac.uk

prw@liverpool.ac.uk

**Corresponding author**

Miss Karen Barnes, MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool L69 3GL, UK

+44 (0)151 794 9753

Karen.Barnes@liverpool.ac.uk

**Abstract**

**Objective**

To evaluate citation analysis as an approach to measuring core outcome set (COS) uptake, by assessing whether the number of citations for a COS report could be used as a surrogate measure of uptake of the COS by clinical trialists.

**Study Design and Setting**

Citation data were obtained for COS reports published before 2010 in five disease areas (systemic sclerosis, rheumatoid arthritis, eczema, sepsis and critical care, and female sexual dysfunction). Those publications identified as a report of a clinical trial were examined to identify whether or not all outcomes in the COS were measured in the trial.

**Results**

Clinical trials measuring the relevant COS made up a small proportion of the total number of citations for COS reports. Not all trials citing a COS report measured all the recommended outcomes. Some trials cited the COS reports for other reasons, including the definition of a condition or other trial design issues addressed by the COS report.

**Conclusion**

While citation data can be readily accessed, it should not be assumed that the citing of a COS report indicates that a trial has measured the recommended COS. Alternative methods for assessing COS uptake are needed.

**Key words:** core outcome set, uptake, citation analysis, clinical trials

**Running title:** Citation analysis for core outcome set uptake

**Word count:** 4319

**“What is new”**

**Key findings:**

1.       COS reports are mostly cited by publications that are not reports of trials

2.       Not all trials citing a COS report have measured the outcomes in the COS

**What this adds to what is known:**

3.       Citation analysis does not provide a reliable assessment of COS uptake by trialists

**What is the implication, what should change now:**

4.       An efficient method to assess COS uptake based on current data needs to be developed

1. **Introduction**

Inconsistency in the outcomes measured and reported across clinical trials in the same health condition creates difficulties for those drawing on the data produced by those studies to make informed decisions about healthcare. Variation in the outcomes selected hinders efforts to synthesise evidence from different trials and allows the potential for outcome reporting bias, the reporting of a sub-set of the outcomes measured based on results1.

To help overcome these problems, the use of an agreed standardised set of outcomes, a core outcome set (COS), is recommended2. A COS consists of those outcomes considered to be most relevant for a specific health condition, typically agreed through consensus by a group of key stakeholders, that should be measured and reported, as a minimum, in all clinical trials of that condition2. Improving the consistency of the outcomes measured across trials by using a COS allows evidence from trials to be synthesised, encourages the reporting of all outcomes and, by incorporating outcomes that are most relevant to key stakeholders, ensures that the outcomes measured include the most appropriate.

A systematic review published in 20143 identified 250 reports relating to 198 COS and a recent update of this work found that the figure had increased to 227 COS by the end of 20144. As it is evident that a large number of published COS exist, with more than 100 also in development, it is important to assess their uptake by clinical trials. The continued development of COS that are not subsequently used in clinical trials will contribute to, rather than reduce, waste in research resulting from funding and time being invested in an initiative that is not then implemented. Furthermore, trials, and the eventual users of the reports of those trials, will not realise the benefits that using a COS can provide.

Assessing uptake also provides an opportunity to review and consider revision to a COS where it is evident that a particular outcome in the COS is not being measured or trials are consistently measuring an outcome that is not already included in the COS. Identifying COS with low uptake provides an opportunity to address barriers and facilitators to uptake.

Previous work has assessed the uptake of COS by examining trial reports included in systematic reviews, or identified through literature searches, to establish whether the outcomes in the COS were measured in the trials5-7. This method has proved to be resource-intensive and, because the trial report will have been published several years after the trial’s design stage when outcomes were chosen, it does not provide an up to date assessment of the uptake of a COS. More recently, a study used citations of the COS report to identify reports of trials that may have measured the COS8. As with other previous work, this study examined each individual trial report to assess uptake of the COS making this a lengthy method. However, citation analysis has the potential to provide an efficient method for COS uptake assessment if the number of citations received by a COS report alone could be taken as an indicator of the uptake of the COS.

The aim of our study is to examine the reliability of using citation analysis as a method of measuring COS uptake. In any scientific publication an author will acknowledge the work of others by providing a reference to their publication. The publication referenced receives this acknowledgement in the form of a citation9. Citation analysis involves counting the number of citations received by a publication or author and taking this figure as a surrogate measure of impact10, i.e. the higher the citation count, the greater the impact. Citation analysis has the potential to provide an efficient method to assess the uptake of a COS if the number of citations received by a COS report could be reasonably taken as a surrogate measure of its uptake by trialists.

1. **Methods**
	1. **Selection of a citation analysis tool**

For this study, we selected Scopus as the citation analysis tool. This is in keeping with a review of Scopus, Web of Science and Google Scholar for citation analysis, which found that Scopus includes a wider range of journals and, in a search for a specific publication, Scopus retrieved 20% more citing articles than Web of Science. It was reported that the accuracy of Google Scholar was inconsistent11.

* 1. **Identification of COS reports**

Of the 250 COS reports identified in the original systematic review3, 173 reports, those published in 2009 and earlier, were considered for our citation analysis. This cutpoint was chosen to allow sufficient time for trialists to become aware of the COS, implement it in their study and cite the COS report in the report of their trial by the time of the current analysis.

* 1. **Selection of COS for citation analysis**

Four COS were initially selected to evaluate the suitability of citation analysis for COS uptake assessment. Each COS provided a different aspect of interest to be investigated. A fifth COS was subsequently added to investigate a hypothesis suggested by the first round of evaluation. Appendix 1 details the characteristics of each COS.

* + 1. **Systemic sclerosis**

Systemic sclerosis was selected as a test case to assess the methods to be used for citation analysis and the identification of trials from the citations retrieved. There are just two COS reports for this condition12, 13, neither of which are highly cited, and so the full process could be trialled from start to finish relatively quickly. One of the COS reports focused specifically on outcomes while the other considered outcomes along with other trial design issues.

* + 1. **Rheumatoid arthritis**

Rheumatoid arthritis was selected as this health condition has one of the most recognised COS that was first published in 1993 following the 1992 OMERACT (Outcome Measures in Rheumatology <http://www.omeract.org/>) conference. The COS is reported in seven publications14-20 all of which were included in the analysis, along with three other publications reporting earlier suggestions of COS for the condition21-23. All ten of the COS publications focussed specifically on recommendations for outcomes.

Another reason for the selection of rheumatoid arthritis was that the uptake of the OMERACT COS has been previously assessed by examining trial reports included in Cochrane Reviews5 to determine whether the outcomes in the COS had been measured. We wanted to establish how many of the trial reports that the previous study had found to have measured the COS would have been retrieved using citation analysis. If only a proportion of these trial reports were retrieved this would suggest that not all trials measuring a COS cite a COS publication in their trial report thus bringing into question the scope of citation analysis in identifying trials that had measured a COS.

* + 1. **Eczema**

Eczema was selected as this condition has a well-known COS due to a collaborative group working specifically on the agreement of COS in dermatological conditions, CSG-COUSIN (<https://www.uniklinikum-dresden.de/de/das-klinikum/universitaetscentren/zegv/cousin/>), which is linked to the Cochrane Skin Group. One report relating to the development of a COS for eczema was published before 2009 and its focus was on recommendations for outcomes. The report identified 20 outcome measurements and recommended that only three of these should be used for future studies. We assessed the uptake of the study’s recommendations24.

* + 1. **Sepsis and critical care**

Sepsis and critical care was selected as there are two associated COS reports, one of which specifically focused on the selection and measurement of outcomes25 while the other considered outcomes whilst addressing other clinical trial design issues26. As with the systemic sclerosis example, identifying the difference in citations of these two COS reports may offer some insight into which type of publication is more likely to be accessed and to have its recommendations implemented by trialists.

* + 1. **Female sexual dysfunction**

Following analysis of the first four COS, female sexual dysfunction was added to the evaluation to further investigate the level of citation of a COS report that included recommendations for outcomes alongside recommendations for other trial design issues27.

* 1. **Process**
		1. **Citation analysis**

Publications that cited at least one of the COS reports were identified using Scopus and the references to these publications were exported into Microsoft Excel. Duplicate entries of the same reference, caused by a publication citing more than one COS report, were removed to ensure that a reference to a COS report was not counted more than once. A publication relating to rheumatoid arthritis that had cited both the Felson 199314 and Boers 199417 COS reports, for example, would count as one citation for the COS.

* + 1. **Identifying RCTs**

Cochrane CENTRAL (Cochrane Central Register of Controlled Trials <http://www.cochranelibrary.com/>) was used as a tool to identify which of the citing publications were reports of trials. CENTRAL provides access to reports of randomised and quasi-randomised controlled trials obtained from a variety of published and unpublished sources. Keywords, such as condition, intervention and patient population, from the title of each citing publication were searched under the ‘record title’ option in CENTRAL. Because CENTRAL contains publications other than trial reports, for example, systematic reviews, the abstracts of the articles identified by CENTRAL were screened to verify whether they were reports of trials. The full papers of those identified as trial reports following the abstract check were obtained for further investigation into why the COS report was cited and whether the outcomes in the COS were measured, to determine whether the citations received by a COS report could be reasonably attributed to trials measuring the COS. To confirm the eligibility of trial reports being included in the study, and the assessment of outcomes included in the trial by the reviewer (KB), the reports identified for rheumatoid arthritis were cross-checked with those identified in the previous rheumatoid arthritis uptake study. In cases where the same reports were identified the outcomes deemed to be measured by the trials were compared and there was 100% agreement between the findings of this and the previous study.

1. **Results**
	1. **Identifying trial reports from the citations**

For each of the disease areas, the search of CENTRAL enabled publications listed in the citation report that were not reports of trials to be removed. The accuracy with which CENTRAL identified trials varied between disease areas (Table 1). CENTRAL was least accurate in identifying rheumatoid arthritis trials, with 126 (53%) of the 236 publications identified by CENTRAL confirmed as reports of trials. It was most accurate for eczema, with six (86%) of the seven records identified being confirmed as trial reports when the abstracts had been screened manually.

**Table 1 – Figures from citation analysis for each disease area**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Disease name** | **Type of publication** | **No. of citations for COS reports**  | **No. of citations identified as possible trials (CENTRAL)** | **No. of citations confirmed as trials (abstract check)** | **No. (%) of trials measuring all outcomes in COS** | **% of citations from trials** |
| Systemic sclerosis | COS-only | 27 | 1 | 0 | 0 (0%) | 0% |
| General design issues | 97 | 15 | 10 | 0 (0%) | 10% |
| Rheumatoid arthritis | COS-only | 1472 | 236 | 126 | 98 (78%) | 9% |
| Eczema | COS-only | 136 | 7 | 6 | 6 (100%) | 4% |
| Sepsis and critical care | COS-only | 64 | 4 | 4 | 1 (25%)  | 6% |
| General design issues | 711 | 23 | 13 | 0 (0%) | 2% |
| Female sexual dysfunction | General design issues | 723 | 40 | 23 | 6 (26%) | 3% |

* 1. **Number of trials identified that measured the COS**

Not all of the citing publications that were identified as trials measured the recommended COS (Table 1). For three of the disease areas (systemic sclerosis, sepsis and critical care and female sexual dysfunction), less than a third of the trials citing a COS report measured all the recommended outcomes. None of the ten trials citing the report on general trial design issues for systemic sclerosis measured the COS, 25% of the four trials citing the COS-only report and none of the 13 trials citing the general trial design issues report for sepsis and critical care measured the COS and 26% of the 23 trials citing the general trial design issues report for female sexual dysfunction measured the COS. In contrast, 78% of the 126 trials citing a COS-only report for rheumatoid arthritis measured all the outcomes in the COS and all 6 trials citing the outcomes-only report for eczema followed its recommendations on outcomes.

Assessment of a random sample of trial reports that had cited a COS report but did not measure all the recommended outcomes (a maximum of five reports for each condition and type of COS report, where available) identified a variety of reasons for citing the COS report (Table 2). Few of the trials were citing the COS report in relation to outcomes. The majority were referencing recommendations about other trial design issues that had been addressed in the COS report, for example, patient inclusion criteria, or definition of a disease or disorder. Some of the trials referencing a COS report that had focussed only on outcomes had measured some of the COS outcomes, and cited the report for this reason, but did not provide an explanation for not measuring all of the recommended outcomes.

**Table 2 – Reasons that trials not measuring the COS cited COS reports**

|  |  |
| --- | --- |
| **Disease area** | **Reason for citing COS report** |
| Systemic sclerosis (general trial design issues report)\*1 | Acknowledging that clinical trials are recognised to be difficult in the disease area |
| Patient inclusion criteria (2 trials) |
| Patient population |
| Determination of disease onset |
| Rheumatoid arthritis (COS-only reports) | Acknowledged COS but limited the number of outcomes to three that could be obtained by self-assessment by the patients |
| The patient’s global status and level of overall pain and the physician’s global assessment were scored on a visual-analogue scale. |
| Measured the core set of measures apart from radiographs in trial lasting more than one year. The trialists acknowledged that this should be done in future trials. |
| The variables chosen included 4 of 7 measures proposed for assessing disease activity by the ACR in 1993. |
| Problems with outcomes have been addressed with the development of a COS |
| Sepsis and critical care (COS-only report)\*2 | Named some of the proposed COS outcomes |
| Inflammatory markers can provide additional support for a phase III study |
| Sensitivity of organ dysfunction scales |
| Sepsis and critical care (general trial design issues report) | Definition of sepsis (4 trials) |
| Patient inclusion criteria |
| Female sexual dysfunction (general trial design issues report) | Definition of female sexual arousal disorder (3 trials) |
| Definition of hypoactive sexual desire disorder (2 trials) |

\*1 There were no citing trials for the systemic sclerosis COS-only report so no sample available

\*2 Three citing trials were available for the sepsis and critical care COS-only report that did not measure the COS

* 1. **Type of COS report cited in trial reports**

For disease areas where two types of COS report exist, i.e. reports focusing only on outcomes and reports considering outcomes whilst addressing other clinical trial design issues, the general design issue reports received more citations from trials (systemic sclerosis n=10, sepsis and critical care n=13) than the outcomes specific reports (systemic sclerosis n=0, sepsis and critical care n=4). However, none of the trials citing the general design issues papers measured the outcomes recommended. While the COS-only reports for these disease areas also had a low number of citing trials measuring the COS (systemic sclerosis n=0, sepsis and critical care n=1), in cases where there was only one type of report, the outcome specific reports had considerably more citing trials that had followed their recommendations (rheumatoid arthritis 78%, eczema 100%) than a general design issues report (female sexual dysfunction 26%) (Table 1).

* 1. **Comparison of methods of uptake assessment for rheumatoid arthritis trials**

The previous study that examined trial reports included in Cochrane Reviews to assess uptake of the OMERACT COS5 found that 100 of the 350 trials that were identified measured all the outcomes in the COS. When the 350 trial reports were cross-referenced with those in the citation report, it was found that only 25 of these 350 trials had actually cited a COS report (Table 3). Therefore, for this particular sample of trials, citation analysis returned an uptake figure of 25 out of 350 trials, whereas 100 of these 350 trials had actually measured the outcomes in the COS. Further comparison of the trials shows that 20 of the 25 identified by citation analysis measured the outcomes in the COS.

**Table 3 – Comparison of uptake for 350 rheumatoid arthritis trials identified in Cochrane Reviews**

|  |  |  |
| --- | --- | --- |
|  | **Cochrane reviews method** | **Citation analysis method** |
| **No. of trials identified** | 350 | 25 |
| **No. (%) of trials that measured the COS** | 100 (29%) | 20 (6%) |

* 1. **Citations received from publications other than trial reports**

For each of the disease areas we assessed, a large proportion of the citations received by the COS reports were from publications reporting on something other than trials (Table 1). For both types of COS report in all of the disease areas, at least 90% of the citations were not from reports of trials.

1. **Conclusions**

The aim of our study was to evaluate whether citation analysis would provide an efficient method to assess COS uptake. While we have been able to demonstrate that citation data can be readily accessed, further investigation shows that it is not possible to assume that the citations received by COS reports are from trials measuring the COS they recommend. For example, of the 775 citations received by the sepsis and critical care COS reports, only 17 were from trials and of these 17 trials just one measured the COS recommended by the report they had cited. These figures demonstrate first that COS reports are not only cited in trial reports but also in other types of publications and secondly that a trial report may cite a COS report for reasons other than adopting the COS, for example, other aspects addressed in the COS report such as patient inclusion criteria and definition of a disease. Therefore, it is not possible to use the number of citations received by a COS report alone as a surrogate measure for uptake of the COS by trials. Additional steps are required to generate an indication of uptake, as discussed below.

Further assessment of each citing publication was needed to establish whether it is a trial report and using CENTRAL to determine this can be a lengthy process. Key words from each publication title needed to be manually input and in cases such as the rheumatoid arthritis example, which has 1472 records, this was time consuming. As it is evident that CENTRAL contains publications other than trial reports, it is necessary to conduct further screening of abstracts to verify those publications identified in CENTRAL. The accuracy of CENTRAL to identify trials relies in part on the input of individual Cochrane Review Groups and it is evident that there are differences in the maintenance of records and therefore the accuracy of CENTRAL between disease areas.

When all citing trials have been identified, an assessment of the trial report is needed to determine whether all the outcomes in the recommended COS were measured, adding a further time consuming stage to the process as with other previous methods.

A recent study assessing uptake of The Prevention of Falls Network Europe (ProFaNE) COS for fall injury prevention8 used citation analysis to identify trials citing the report of the COS. Similar to the disease areas reported here, a small proportion of the citations received by the COS report were from trials, with 34 trials found in 464 citations. The 34 trials were identified by screening the citing article’s titles and abstracts and excluding reports that were protocols, pilot studies or secondary reports of a trial already extracted. The majority of citing articles were observational studies (46%), editorials or reviews (23%) or methodological articles (13%). Analysis of the trial reports found that the majority of trials made reference to the COS report in relation to other recommended methodology, for example, length of follow up period, rather than outcomes. This finding is echoed in the study reported here, where COS reports are often referenced for design issues that had been addressed in addition to outcomes. Analysis of the ProFaNE COS also found that, while most trials had reported at least one of the recommended core domains, only one trial had reported on all core domains.

The results of the ProFaNE COS study support our finding that the number of citations received by a COS report cannot be taken as an indicator of its uptake and that further analysis is needed to ascertain whether the citing articles are trials measuring the COS. The number of steps and the amount of time needed to complete this process means that citation analysis is no more efficient for uptake assessment than the method of examining trial reports used previously5-7. Rather, citation analysis provides an alternative method of identifying trial reports that can then be assessed. Both citation analysis studies highlight that COS reports are mostly cited in articles that are not trial reports and it would be of interest to further investigate the types of articles citing COS reports and their reasons for doing so.

In addition to these findings, there are additional limitations of citation analysis for COS uptake assessment that should be noted.

Citation analysis does not take into account those trials that did measure the outcomes in a COS but did not cite a COS report thus affecting the accuracy of citation analysis as an indicator of uptake. As demonstrated by the comparison of methods to assess uptake of the rheumatoid arthritis COS, not all trials that measure a COS cite a COS report. This would lead to the rate of COS uptake being underestimated by citation analysis. In the case of the rheumatoid arthritis COS, a study previously demonstrated that 100 trials from a particular sample of 350 measured the COS5. However, when we cross referenced this same sample with the citation report, only 20 of the trials that had measured the COS were present, plus a further five from the sample that had not measured the COS. Identifying a sample of trials and taking the number that had cited a COS report as a surrogate measure of COS uptake would remove the time consuming process of examining the full trial report. However, this rheumatoid arthritis example demonstrates that uptake rate assessed in this way could be greatly underestimated. Regardless of which method is used to identify trials for assessment of COS uptake, whether through Cochrane Reviews, literature searchers or citation analysis, it is not possible to avoid a full examination of the trial report to obtain an accurate assessment of whether the outcomes in the COS had been measured. Therefore, it is necessary to consider ways in which examining trial reports can become more streamlined. This could be achieved if the format of trial reports allowed the outcomes measured in the trial to be clearly annotated so that it would not be necessary to read the full report to extract the information required.

A further limitation of citation analysis for COS uptake is the absence of data on the number of trials that were conducted in the relevant health condition for the time period being investigated. To make an accurate assessment of uptake it is necessary to know the proportion of the total number of trials that used the COS. Citation analysis can only retrieve information about trials that have cited a COS publication and does not provide the total number of trials conducted as a denominator.

Along with the evaluation of citation analysis as a method for assessing COS uptake, our findings raise an interesting hypothesis in relation to the effect that the focus of a COS report may have on COS uptake. Of the two COS reports for systemic sclerosis, one considered outcomes while addressing other clinical trial design issues12 whereas the other focused specifically on the selection of outcomes13. Table 1 shows that none of the citing trials cited the outcomes specific paper and although this might be expected as that COS report was published in 2008 and the latest trial report identified was published in 2011, it generated a hypothesis that a COS recommended in a general clinical trial design publication is more likely to be implemented. However, further investigation shows that none of the trials citing the general clinical trial design paper measured the COS. They had cited the paper in relation to other design issues, for example, patient population and inclusion criteria, and not in relation to the choice of outcomes. Further investigation into the measurement of outcomes in a COS by trials that cited a general design issues publication for female sexual dysfunction revealed that 26% of trials citing the publication measured the COS. In contrast, 100% of trials that cited the eczema report and 78% of trials that cited a rheumatoid arthritis COS report, all of which focused specifically on the selection of outcomes, followed the report’s recommendations on outcomes. It may be that when choice of outcomes is one of several issues addressed by a report, the recommendations relating to outcomes may become lost in the volume of information provided by the publication. Trialists looking specifically for advice on a particular area of trial design may overlook the recommendations regarding outcomes in these reports. Although reports focussing only on choice of outcomes may not be as highly cited as those covering a wider range of issues, the trialists citing these reports may be more likely to follow the recommendations in relation to which outcomes to measure. This may suggest that a COS should be reported independently of other design issues to attract the most attention, but this hypothesis requires further investigation.

It would also be of interest to further investigate which COS are measured in full, and compare their shared characteristics with those of COS that are only partially measured. This comparison may point to characteristics of COS that could affect their uptake in full. For example, none of the trials that cited the systemic sclerosis COS measured it in full. However, all of the trials measured at least one of the outcomes in the COS and the maximum measured in any one trial was six. Appendix 1 shows that this particular COS includes 14 outcomes and its partial use may be as a result of 14 outcomes being too many to include in a trial. Further investigation into fully and partially measured COS may indicate a maximum number of outcomes that should be included to enable trials to implement the full COS.

**Future work**

It is important to continue to consider efficient methods to assess the uptake of COS. Examining trial reports does not provide an up to date picture of COS uptake and it is of interest to investigate methods that can identify outcomes that trialists are choosing for their studies at the present time, rather than those chosen at some time in the past. Clinical trial registries have the potential to provide an efficient assessment of COS uptake based on current information about the outcomes being measured in trials. A recent proposal suggested that trial registries could encourage trialists to record their use of a COS when registering their trial28. This information would provide a valuable resource allowing uptake of COS in ongoing trials to be assessed.

**Acknowledgements**

This work was supported by the MRC Network of Hubs for Trials Methodology Research (MR/L004933/1- Q30) and the MRC North West Hub for Trials Methodology Research (MR/K025635/1).

**References**

1. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance of research through the use of agreed core outcomes. *Journal of Health Services Research and Policy* 2012;17(1):1-2.

2. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: Issues to consider. *Trials* 2012;13.

3. Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke M, et al. Choosing important health outcomes for comparative effectiveness research: A systematic review. *PLoS ONE* 2014;9(6).

4. Gorst SL, Gargon E, Clarke M, Blazeby JM, Altman DG, Williamson PR. Choosing important health outcomes for comparative effectiveness research: An updated review and user survey. *PLoS ONE* 2016;11(1).

5. Kirkham JJ, Boers M, Tugwell P, Clarke M, Williamson PR. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. *Trials* 2013;14(1).

6. Bautista-Molano W, Navarro-Compán V, Landewé RBM, Boers M, Kirkham JJ, Van Der Heijde D. How well are the ASAS/OMERACT core outcome sets for ankylosing spondylitis implemented in randomized clinical trials? A systematic literature review. *Clinical Rheumatology* 2014;33(9):1313-22.

7. Mulla SM, Maqbool A, Sivananthan L, Lopes LC, Schandelmaier S, Kamaleldin M, et al. Reporting of IMMPACT-recommended core outcome domains among trials assessing opioids for chronic non-cancer pain. *Pain* 2015;156(9):1615-9.

8. Copsey B, Hopewell S, Becker C, Cameron ID, Lamb SE. Appraising the uptake and use of recommendations for a common outcome data set for clinical trials: A case study in fall injury prevention. *Trials* 2016;17(1).

9. Smith LC. Citation analysis. *Library Trends* 1981;30(1):83-106.

10. Marx W, Schier H, Wanitschek M. Citation analysis using online databases: Feasibilities and shortcomings. *Scientometrics* 2001;52(1):59-82.

11. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: Strengths and weaknesses. *FASEB Journal* 2008;22(2):338-42.

12. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma): I. Disease-modifying interventions. *Arthritis and Rheumatism* 1995;38(3):351-60.

13. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. *Annals of the Rheumatic Diseases* 2008;67(5):703-9.

14. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis and Rheumatism* 1993;36(6):729-40.

15. Fried BJ, Boers M, Baker PRA. A method for achieving consensus on rheumatoid arthritis outcome measures: The OMERACT conference process. *Journal of Rheumatology* 1993;20(3):548-51.

16. Tugwell P, Boers M. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. *Journal of Rheumatology* 1993;20(3):555-6.

17. Boers M, Tugwell P, Felson DT, Van Riel PLCM, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *Journal of Rheumatology* 1994;21(SUPPL. 41):86-9.

18. Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmèn M, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. *Journal of Rheumatology* 2003;30(4):868-72.

19. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - Progress at OMERACT 7. *Journal of Rheumatology* 2005;32(11):2250-6.

20. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, De Wit M, et al. Patient perspective: Fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. *Journal of Rheumatology* 2007;34(5):1174-7.

21. Bombardier C, Tugwell P, Sinclair A, Dok C, Anderson G, Buchanan WW. Preference for endpoint measures in clinical trials: results of structured workshops. *Journal of Rheumatology* 1982;9(5):798-801.

22. Scott DL, Spector TD, Pullar T, McConkey B. What should we hope to achieve when treating rheumatoid arthritis? *Annals of the Rheumatic Diseases* 1989;48(3):256-61.

23. Van Riel PLCM. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis. *British Journal of Rheumatology* 1992;31(12):793-4.

24. Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. *Journal of Allergy and Clinical Immunology* 2007;120(6):1389-98.

25. Marshall JG, Vincent JL, Guyatt G, Angus DC, Abraham E, Bernard G, et al. Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. *Critical Care Medicine* 2005;33(8):1708-17.

26. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. *Pediatric Critical Care Medicine* 2005;6(1):2-8+96-8.

27. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et al. Report of the international consensus development conference on female sexual dysfunction: Definitions and classifications. *Journal of Urology* 2000;163(3):888-93.

28. Clarke M, Williamson P. Core outcome sets and trial registries. *Trials* 2015;16(1).